GLP-1 MEDICATIONS AND HEART HEALTH: WHAT THE SELECT TRIAL PROVED

The Cardiovascular Breakthrough

In March 2024, the FDA approved Wegovy (semaglutide 2.4mg) for cardiovascular risk reduction in adults with obesity and established heart disease — making it the first weight loss drug to earn this indication. The approval was based on the SELECT trial, one of the largest cardiovascular outcomes trials ever conducted for an obesity medication.

For men, who develop cardiovascular disease earlier and die from it more frequently than women, this data is especially significant.

SELECT Trial: The Numbers

The SELECT trial enrolled 17,604 adults with overweight or obesity and established cardiovascular disease (but without diabetes) and followed them for a mean of 39.8 months. The results:

• 20% reduction in major adverse cardiovascular events (MACE) — heart attack, stroke, and cardiovascular death combined
• Benefits appeared within three months of starting treatment, before significant weight loss occurred
• Heart attacks specifically were reduced by approximately 28%
• All-cause mortality trended lower, though the study wasn’t powered to detect this definitively

The speed of benefit onset — within three months — suggests that GLP-1s have direct cardiovascular protective effects beyond what weight loss alone would explain. Researchers believe this involves anti-inflammatory mechanisms, improved endothelial function, and reduced arterial plaque instability.

Blood Pressure and Cholesterol Improvements

Beyond the headline MACE reduction, GLP-1 medications consistently improve the cardiovascular risk factors that men struggle with most:

• Blood pressure: Semaglutide reduced systolic blood pressure by 3–5 mmHg on average in clinical trials. For men with borderline hypertension, this can be the difference between needing medication and not.
• Triglycerides: Reductions of 15–25% are typical, addressing one of the most common lipid abnormalities in obese men.
• LDL cholesterol: Modest reductions, amplified when combined with statin therapy.
• CRP (C-reactive protein): A marker of systemic inflammation. GLP-1s reduce CRP levels significantly, indicating lower overall inflammatory burden.
• Waist circumference: Visceral fat is the most dangerous fat type for cardiovascular health, and GLP-1s preferentially target it. The BELIEVE trial showed 58% visceral fat reduction with combination therapy.

Beyond SELECT: The Broader Picture

The SELECT trial isn’t the only cardiovascular evidence. The FLOW trial demonstrated kidney-protective effects. The SURMOUNT-OSA trials showed sleep apnea resolution — itself a cardiovascular risk factor. And ongoing trials are examining GLP-1s for heart failure with preserved ejection fraction (HFpEF), a condition with few effective treatments.

For men carrying excess weight, the cardiovascular case for GLP-1 therapy goes beyond weight loss. These medications appear to be genuinely protective for the heart and vascular system through multiple mechanisms — a finding that has fundamentally changed how cardiologists think about obesity treatment.